Company Overview and News

Red Violet - Spin Off To $0.00 - Possible Russell 2000 Mistake + Questionable Management

2018-05-10 seekingalpha
We believe Russell 2000 mistakenly included RDVT in the Russell 2000. Index fund removal will likely be announced on May 11 which will lead to forced selling.

Philippines slips a notch in ICT Development Index

2017-11-24 philstar
MANILA, Philippines — The Philippines has slipped one notch in a United Nation agency’s ICT Development Index (IDI).

Superior Plus Announces Acquisition of International Dioxcide, Inc. Expanding its Specialty Chemicals Business

2017-10-13 marketwired
TORONTO, ONTARIO--(Marketwired - Oct. 13, 2017) - Superior Plus Corp. ("Superior") (TSX:SPB) is pleased to announce it has entered into an agreement to acquire all of the issued and outstanding shares of International Dioxcide, Inc. ("IDI") from LANXESS Corporation. IDI provides sodium chlorite based solutions including small-scale chlorine dioxide generation technology for biocidal and oxidative applications in municipal drinking water disinfection, cooling tower treatment, oil and gas fracturing, stimulation and odour control, rendering, paper machine slimicide, process water, wastewater treatment and food processing.

Cogint: An Emerging Player In Big Data

2017-03-02 seekingalpha
According to a report released by market research firm IDC in late 2016, the worldwide big data and analytics market is expected to exceed $200 billion by 2020. This would represent a double-digit increase from 2016. Big data has in fact become a buzz word in the business world. More and more companies are investing heavily in big data and analytics as they look to better manage risks and predict consumer behaviors.

India 60th in WEF inclusive development list below Nepal, Pakistan

Davos : India has been ranked 60th among 79 developing economies, even lower than China and Pakistan, in the World Economic Forums latest inclusive development index (IDI) report.

IDI loss widens; data fusion release set for Q4

2016-09-18 seekingalpha
IDI Inc. (IDI +6.5%) posted a wider net loss in its Q3 results after a large gain in G&A expenses as it worked to build a data fusion business.

9 Analyst Stocks Under $10 With Massive Upside Calls

2016-07-17 247wallst
The week of July 15 amazingly brought new highs for the S&P 500 and the Dow Jones Industrial Average. Many investors have supposedly gotten out of many stocks, and there have been many unusual hurdles for the current bull market. The reality is that investors are still looking for ways to find value and make money.

IDI Inc. And TransUnion Enter Into Settlement Negotiations

2016-06-20 seekingalpha
Today, Monday June 20, 2016, IDI, Inc. (IDI) an emerging company in the data fusion and digital marketing industry and TransUnion (TRU), the credit agency and consumer data behemoth have entered in court mandated settlement discussions. Judge Paul G Hyman, Jr., Chief United States Bankruptcy Judge signed this order in his court on May 26, 2016. His signed order can be seen here:

Unum Group's (UNM) CEO Rick McKenney on Q1 2016 Results - Earnings Call Transcript

2016-04-28 seekingalpha
Welcome to the Unum Group first quarter 2016 earnings conference call. Today's conference is being recorded. At this time, for opening remarks and introductions, I would like to turn the conference over to the Senior Vice President Investor Relations, Mr. Tom White. Please go ahead, sir.


2016-04-13 caselaw.findlaw
In the midst of the 2008–09 financial crisis, a Wisconsin bank called AnchorBank was struggling to stay above water. Under pressure to find cash to pay its own lenders, the bank's president told vice president David Weimert to try to sell the bank's share in a commercial real estate development in Texas. Weimert, who is the defendant and appellant in this criminal wire fraud case, successfully arranged a sale that exceeded the bank's target price by about one third.

IDI Form SC 13G/A (Acquisition of More Than 5% of Shares)

SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     IDI, Inc. (Name of Issuer) Common Stock, $0.0005 par value per share (Title of Class of Securities) 44938L108 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   a.

IDI Form DEF 14C

DEF 14C Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934       Check the appropriate box: ¨   Preliminary Information Statement ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x   Definitive Information Statement IDI, INC.

IDI Form EX-99

Exhibit 99 JOINT FILER INFORMATION NAME: Frost Gamma Investments Trust ADDRESS: 4400 Biscayne Blvd. Miami, FL 33137 Designated Filer: Phillip Frost, M.D. Issuer and Ticker Symbol: IDI, Inc. (IDI) Date of Event Requiring Statement: January 27, 2016 FROST GAMMA INVESTMENTS TRUST by: /s/ Phillip Frost, M.D. Phillip Frost, M.D., Trustee

IDI Form EX-99

Exhibit 99 JOINT FILER INFORMATION NAME: Frost Gamma Investments Trust ADDRESS: 4400 Biscayne Blvd. Miami, FL 33137 Designated Filer: Phillip Frost, M.D. Issuer and Ticker Symbol: IDI, Inc. (IDI) Date of Event Requiring Statement: January 26, 2016 FROST GAMMA INVESTMENTS TRUST by: /s/ Phillip Frost, M.D. Phillip Frost, M.D., Trustee


Mail Stop 3720 December 22, 2015 Aaron Solomon Chief Financial Officer IDI, Inc. 2650 North Military Trail, Suite 300 Boca Raton, Florida 33431 Re: IDI, Inc. Form 10-K for Fiscal Year Ended December 31, 2014 Filed April 15, 2015 File No. 333-158336 Dear Mr. Solomon: We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

7h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...